Loading...
01/11 05:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed declines in core revenues across segments, a significant goodwill impairment, and a lowered EBITDA. Despite some positive updates, like pathogen testing growth and reduced CapEx, the overall sentiment is negative due to the weak financial performance and market outlook. The Q&A highlighted concerns about tariffs and macroeconomic pressures, further dampening investor sentiment. With a market cap of $3.45 billion, the stock is likely to experience a negative reaction, falling within the -2% to -8% range over the next two weeks.
Fourth Quarter Revenues $225 million, Core revenue down 290 basis points year-over-year due to foreign currency and discontinued products, which were a headwind of 190 basis points.
Food Safety Segment Revenues $162 million, down 3% year-over-year, Core revenue declined 1.3%. Growth in biosecurity and pathogen detection products offset by declines in sample collection and Petrifilm.
Animal Safety Segment Revenues $64 million, Core revenue declined 6.7% year-over-year. Growth in small animal supplements and rodenticides offset by declines in other major products.
Genomics Core Revenue Declined low single digits year-over-year. Sequential improvement due to refocusing on attractive end markets.
Gross Margin 41.2%, impacted by lower volume, elevated inventory write-offs, production inefficiencies, and tariff impacts.
Adjusted EBITDA $41 million, margin of 18%, negatively impacted by inventory write-offs, tariffs, and production inefficiencies.
Adjusted Net Income $11 million, down from $22 million year-over-year, due to lower adjusted EBITDA.
Adjusted Earnings Per Share $0.05, down from $0.10 year-over-year, primarily due to lower adjusted EBITDA.
Goodwill Impairment $598 million noncash charge due to weakened end market conditions, global trade impacts, and production execution issues.
Free Cash Flow Roughly breakeven, improved $14 million sequentially but lower than anticipated due to lower EBITDA and timing of CapEx.
Launch of Listeria Right Now: Neogen announced the launch of Listeria Right Now for use on its MDS platform for pathogens. This system provides fast detection of environmental pathogens in up to 96 samples per cycle, utilizing loop-mediated isothermal amplification.
Petrifilm Facility Progress: The new Petrifilm facility is progressing well, with initial testing production expected to begin in a few months. Once fully operational, it is expected to improve gross margins slightly compared to current production methods.
Food Safety Market Conditions: The Food Safety market is experiencing slower growth due to cumulative inflation and reduced production volumes among food producers. Regulatory cuts at USDA and FDA have impacted certain areas, but food safety testing remains a priority.
Animal Safety Market Challenges: The Animal Safety market is in a cyclical trough, with the cattle herd at a 70-year low. Veterinary distributors and ag retailers are cautious due to broader market uncertainty.
Sample Collection Production Challenges: Production inefficiencies in sample collection have led to high costs and manual labor reliance. Efforts are underway to address these issues, including potential involvement of global manufacturing partners.
Inventory Planning Improvements: Neogen is implementing more robust inventory planning and coordination to reduce elevated inventory write-offs and improve operational efficiency.
Divestiture of Non-Core Businesses: Neogen is divesting its genomics business and recently completed the divestiture of its cleaners and disinfectants business to simplify operations and focus on core areas.
Targeted Improvement Plan: A near-term blueprint has been released to manage the transition period, focusing on building a more profitable and focused Neogen.
End Market Conditions: Worsened conditions in the Food Safety segment due to cumulative inflation over the last 4 years, leading to year-over-year declines in production volumes for food producers. This trend is not expected to reverse meaningfully in the near future.
Regulatory Environment: Cuts at USDA and FDA have impacted areas like avian flu testing and local food assistance programs, though food safety testing remains a priority. Uncertainty exists around the implementation of new Salmonella frameworks.
Animal Safety Segment: The cattle herd size, a key driver for the segment, is at a 70-year low, leading to a cyclical trough in the market. Veterinary distributors and ag retailers are cautious due to broader market uncertainty.
Global Trade Environment: Uncertainty in global trade, particularly with China, has impacted food producers' import/export planning and distributors' purchase decisions. Tariffs are expected to have a $10 million annualized impact.
Sample Collection Production: Significant inefficiencies in production due to aging equipment and reliance on manual processes, leading to high costs, excessive scrap rates, and inconsistent output.
Integration of 3M Food Safety Business: Execution shortfalls in the integration process have been exacerbated by soft market conditions, foreign currency headwinds, and global trade challenges.
Inventory Management: Elevated inventory write-offs and inefficiencies in inventory planning have negatively impacted gross margins and adjusted EBITDA.
Petrifilm Production: Challenges in transitioning production to a new facility, with potential impacts on overhead absorption rates and gross margins.
Revenue Expectations: Revenue for fiscal year 2026 is expected to be between $820 million and $840 million, excluding the revenue from the divested cleaners and disinfectants business.
Adjusted EBITDA Projections: Adjusted EBITDA is projected to range between $165 million and $175 million for fiscal year 2026, excluding the impact of the divested cleaners and disinfectants business.
Gross Margin Outlook: Gross margin in fiscal 2026 is expected to benefit from lower inventory write-offs but will face headwinds from sample collection inefficiencies and tariffs. Higher adjusted EBITDA margins are anticipated in the second half of the year due to improvements and seasonality.
Capital Expenditures: Capital expenditures are expected to decline significantly to approximately $50 million in fiscal 2026, compared to fiscal 2025.
Free Cash Flow: Free cash flow is expected to be positive in fiscal 2026, supported by reduced capital expenditures.
Market Conditions: The company does not anticipate meaningful improvement in end market conditions for fiscal 2026, with continued pressure from elevated inflation and weak food production levels. The Animal Safety market is expected to remain in a cyclical trough.
Trade Environment: The global trade environment is expected to remain dynamic, with an annualized tariff impact estimated at $10 million.
Production and Efficiency Improvements: The company plans to address inefficiencies in sample collection production and expects gradual improvements over the coming quarters. The new Petrifilm facility is expected to begin initial testing production in a few months, with full production anticipated to improve gross margins slightly.
The selected topic was not discussed during the call.
The earnings call reveals strong financial performance with improved margins and EBITDA, alongside optimistic guidance. The Q&A section highlights effective management and strategic initiatives, such as the Petrifilm manufacturing process and commercial organization changes. Despite some conservative guidance and ongoing challenges, the overall sentiment is positive, with raised guidance and customer confidence in key product lines. Given the market cap, the stock price is likely to react positively, but not overwhelmingly so.
The earnings call summary presents a mixed picture: while there are positive aspects like the strong performance of Petrifilm and expected EBITDA margin improvement, there are concerns about supply challenges, margin pressures, and a lack of raised guidance despite revenue beats. The Q&A section reveals management's cautious stance, especially regarding early-year uncertainties and execution challenges. These factors, combined with the company's mid-sized market cap, suggest a neutral stock price movement in the short term.
The earnings call revealed declines in core revenues across segments, a significant goodwill impairment, and a lowered EBITDA. Despite some positive updates, like pathogen testing growth and reduced CapEx, the overall sentiment is negative due to the weak financial performance and market outlook. The Q&A highlighted concerns about tariffs and macroeconomic pressures, further dampening investor sentiment. With a market cap of $3.45 billion, the stock is likely to experience a negative reaction, falling within the -2% to -8% range over the next two weeks.
The earnings call reveals several concerning factors: missed EPS expectations, downward revenue and EBITDA guidance, and significant macroeconomic and tariff headwinds. Despite some positive aspects like restructuring efforts and U.S. food safety growth, the lack of a share repurchase program and unclear management responses in the Q&A contribute to a negative sentiment. The company's market cap suggests a moderate reaction, leading to a predicted stock price decline of -2% to -8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
